Twincretin Shows Positive Effects in Phase 3 Trial in Diabetes Twincretin Shows Positive Effects in Phase 3 Trial in Diabetes

Tirzepatide, the first dual GIP and GLP-1 receptor agonist in advanced testing, showed potent antihyperglycemic and weight loss effects in the first of several phase 3 studies in type 2 diabetes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news